About Paranta

About Paranta

Paranta Biosciences Limited is an unlisted Australian biopharmaceutical company developing PB01 as a first-in class biotherapeutic for the prevention of delayed graft function during kidney transplantation.

PB01, Paranta’s unique recombinant form of human follistatin-288, binds to and inhibits members of the TGF-β superfamily of cytokines, where it modulates the resulting inflammation, fibrosis and metabolic effects.

Paranta was established with the aim of commercializing property based on pioneering research by Monash University on follistatin. This initial research has been pivotal for Paranta's selection & subsequent clinical development of PB01. Paranta has advanced from the discovery to development phase and is now focused on acute kidney injury.

Paranta Biosciences has strong and active collaborative relationships with the Hudson Institute of Medical Research (previously Monash Institute of Medical Research), Monash University and affiliated medical and pharmaceutical institutes.

Paranta Team

Board of Directors
Mr Peter Hodgson
Chairman, Non-Executive Director
Professor David M. de Kretser AC MBBS, MD, HonLLD
Chief Scientist, Non-Executive Director
Dr Jeannette A. Joughin BSc(Hons), PhD, CertMktg
Non-Executive Director
Mr Austin S.E. Miller BSc, LLB, MBA
Non-Executive Director
Mr Ross Barrow BSc(Hons), MBA
Chief Executive Officer, Director
Mr Brendan E. Brown BBus, CA
Company Secretary
Management Team
Medical Advisors

The intellectual founding father of Paranta Biosciences who led the medical research team that first isolated follistatin and performed pioneering research on the structure, physiology and role of inhibins, activins and follistatin.

Professor David M. de Kretser

Corporate Timeline

Paranta Biosciences corporate timeline

Since the company commenced operations in 2011, we have reached many key milestones. Click through to see some of our major achievements.

2019

Transitioned from Discovery to Development Phase company.

Focus on developing current formulation of PB01 for preventing delayed graft function during kidney transplantation.

2018

Positive preclinical results in models of chronic kidney disease.

US and European patents granted, covering organ transplantation.

2017

US Cystic Fibrosis Foundation Therapeutics Development Award.

PB01 (inhaled) Phase 1 LPS challenge clinical trial completed in the UK. Safety & tolerability established in healthy volunteers.

2016

PB01 (inhaled) phase 1 SAD / MAD clinical trial completed. Safety and tolerability established in healthy volunteers.

2015

Paranta manufactures the first cGMP batch of PB01.

PB01 (i.v.) kidney disease research collaboration established with McMaster University, Canada.

2014

Preclinical safety & toxicology studies for inhaled PB01 undertaken in Canada.

Positive preclinical results in ischemia reperfusion injury (IRI) model of organ transplantation.

2013

Efficacy established in preclinical models of lung disease.

2011

First employee.

2009

Company established.

1987

Follistatin is discovered.

address

Paranta Biosciences Limited
Suite 549, 1 Queens Rd
Melbourne, VIC 3004
Australia
T (03) 9863 9070

email alerts

quick search